Actinium Pharmaceuticals (ATNM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Actinium Pharmaceuticals’ strategic advancements and financial stability. Actinium is making significant strides in the field of targeted radiotherapies, particularly with its latest development, ATNM-400, which targets prostate cancer using a novel non-PSMA approach. This innovation positions Actinium to potentially offer alternative treatments in the lucrative post-Pluvicto market, where current options are limited to chemotherapy.
Furthermore, Actinium’s expansion into solid tumor indications and its involvement in both ADC and radiopharma sectors underscore its growth potential. The company’s robust pipeline, including ongoing studies in hematological cancers, and its strong financial position, with $79 million in cash and no debt, provide a solid foundation for future developments. These elements, combined with the stock trading below cash value, suggest that Actinium could be an undervalued opportunity in the biotech space.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.